1/11
Looks like no tags are added yet.
what are proteins modifications
can be made to protein drugs to improve stability, efficacy, pharmacokinetics
may be engineered using recombinant DNA tech or by chemical modification of protein
eg fusion proteins, antibody drug conjugates, humanisation of MABs, modified insulins
describe protein modifications in insulin
regular insulin exists in hexameric form-after subcutaneous injection must dissociate for absorption
modifications to insulin may change quaternary structure eg:
long acting-promote hexamer formation, reduce solubility, promote binding to plasma proteins
fast acting-prevent formation of dimers and hexamers=increase solubility
what is PEGylation of therapeutic proteins
the process of attaching polyethylene glycol (PEG) polymer chains to a therapeutic protein, peptide, or antibody
hydrophilicity and flexibility of PEG
hydrophilicity-improved solubility, reduced protein binding, improved bioavailability, avoids phagocytosis
flexibility-shielding antigenic sites, lower toxicity, proteolytic resistance, reduced clearance, better thermal and mechanical stability
specificity of PEGylation of therapeutic protein
can negatively affect protein activity
site specific PEGylation can occur so functional parts of protein not blocked:
PEGylation of N-terminus without cross reacting with lysine residues at 8.5pH
describe PEGylated insulin analogue
long acting, once daily basal insulin
PEGylation:
-reduces diffusion rate
-reduces renal clearance
-better stability vs proteases
phase I trials found glucose normalisation and dose reduction
significant reduction in HbA1c
liver specific action
but some showed increased fat content in liver
describe spray drying as an alternative formulation
continuous process whereas lyophilisation is batch
gentler
forms powder-don't need milling or sieving
particle size can be adjusted=changes dissolution rate
can be done aseptically
may allow room temp storage
describe nanoparticles as emerging protein delivery techs
polymer and lipid based nanoparticles-can encapsulate proteins
interest in many routes inc oral
can be modified with shielding molecules and targeting ligands-may facilitate intracellular delivery
avoid phagocytosis-alters particle size
describe polymeric controlled drug delivery systems
used for controlled protein delivery over long time-protein released as polymer degrades
most widely used polymers=hydrophobic and only soluble in organic solvents-not good for biologicals
need to generate emulsions to get hydrophilic biological drug into hydrophobic polymer
problems with polymeric controlled drug delivery systems
interfaces with air, solvents, surfaces, temp, degradation products at release site
what is micro-scale delivery
device implanted during out patient visit
each reservoir has 40 micrograms of drug
what is cell based protein delivery
allogenic cells
long term delivery
high cell density